Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
54 hedge funds and large institutions have $50.6M invested in Tourmaline Bio in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 8 closing their positions.
84% more capital invested
Capital invested by funds: $27.5M → $50.6M (+$23.1M)
38% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 13
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 53 → 54 (+1)
0.02% more ownership
Funds ownership: 6.43% → 6.46% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$3.18M |
| 2 |
Citigroup
New York
|
+$1.4M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$967K |
| 4 |
Morgan Stanley
New York
|
+$431K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.09M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.9M |
| 3 |
Two Sigma Investments
New York
|
-$127K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$92K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$89K |
TRML Hedge Fund Activity: Q1 2023 in Review
54 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q1 2023, worth a combined $50.6M — up 84% from $27.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TRML positions and 8 closed out — a net gain of 1 holder — while 18 added to existing stakes and 13 trimmed.
The largest buyer was BML Capital Management, opening a new position worth an estimated $3.18M. The largest seller was Citadel Advisors, cutting an estimated $4.09M.
- 54 institutional investors held Tourmaline Bio (TRML) as of Q1 2023, up from 53 in Q4 2022.
- Funds reported $50.6M of Tourmaline Bio stock for Q1 2023, up 84% quarter-over-quarter.
- 9 funds opened new Tourmaline Bio positions in Q1 2023 and 8 closed out, a net change of +1 holder.
- The largest Tourmaline Bio buyer in Q1 2023 was BML Capital Management, an estimated $3.18M added.
- The largest Tourmaline Bio seller in Q1 2023 was Citadel Advisors, an estimated $4.09M sold.
Based on aggregated 13F filings for Q1 2023.